Towards Retinoid Therapy for Alzheimer’s Disease

K. Shudo\textsuperscript{1,*}, H. Fukasawa\textsuperscript{2}, M. Nakagomi\textsuperscript{1} and N. Yamagata\textsuperscript{1}

\textsuperscript{1}Research Foundation ITSUU Laboratory, \textsuperscript{2}Institute of Medicinal Molecular Design, Inc., Molecular and Functional Bioscience, Japan

Abstract: Alzheimer’s disease (AD) is associated with a variety of pathophysiological features, including amyloid plaques, inflammation, immunological changes, cell death and regeneration processes, altered neurotransmission, and age-related changes. Retinoic acid receptors (RARs) and retinoids are relevant to all of these. Here we review the pathology, pharmacology, and biochemistry of AD in relation to RARs and retinoids, and we suggest that retinoids are candidate drugs for treatment of AD.

Keywords: Alzheimer’s disease, retinoid, retinoic acid receptors, inflammation, immunology, regulatory T cell, neurodegeneration.

TOWARDS RETINOID THERAPY FOR ALZHEIMER’S DISEASE

The management of Alzheimer’s disease (AD) remains a challenge, even as our knowledge and understanding of AD continue to grow at an unprecedented rate [1-3]. Research that bridges the gap between basic science and clinical application is extremely important for the development of new therapeutics. AD is a neurodegenerative disease, and has many pathological, biochemical and immunological features in common with Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and spinal cord injury (SCI). This paper deals mainly with AD in relation to retinoic acid receptors (RARs: RAR\(\alpha\), \(\beta\) and \(\gamma\)) and their ligands (retinoids), such as the endogenous RAR ligand all-trans-retinoic acid (RA), taking into account knowledge about PD, ALS and other neurodegenerative diseases. It is important to note that factors leading to the onset of these diseases are still poorly understood, and so there is a great deal of scope for novel therapeutic approaches. Recent findings indicate that the window of opportunity for enhancing or normalizing the growth of neuronal cells and promoting recovery from neurodegenerative diseases may be larger than previously thought.

AD is associated with a variety of pathophysiological features, including amyloid plaques, inflammation, immunological changes, cell death and regeneration processes, altered neurotransmission, and age-related changes. Here, we will review how retinoids could be involved in all these features of AD, together with the brief summary of their biology, pharmacology, and medicinal chemistry. Fig. (1) shows the overview of the various potential therapeutic targets by retinoids discussed in this paper.

MEDICINAL CHEMISTRY OF RETINOIDS

Retinoids are analogues of retinoic acid, an active metabolite of vitamin A, and are specific modulators of cell proliferation, differentiation, and morphogenesis in vertebrates. There are many excellent reviews of the medicinal chemistry of retinoids [4-10]. The term retinoid is used for substances which may be defined as (1) vitamin A related compounds (including vitamin A (retinol) and its biological precursor carotenoids), (2) RA (vitamin A metabolite), which activates RAR\(\alpha\), \(\beta\), and \(\gamma\), and synthetic analogs which bind with RARs with high affinity in an agonistic (similar biological activities to RA) or antagonistic manner, (3) compounds which activate RXR\(\alpha\), \(\beta\) and \(\gamma\), which are nuclear receptors different from RARs, (4) compounds which modify the activities of RA by influencing metabolism, biosynthesis or other pathways acting on co-factors, without binding to RARs or RXRs. We prefer to use the term retinoid in a strict sense, that is, compounds in category (2). It should be noted that the activity of vitamin A (retinol) is essentially due to RA generated by metabolism in vivo, except for the participation in vision via rhodopsin. [11-13]. Normally, a low level of RA is present (~10\(^{-9}\)-10\(^{-10}\) M), although a much larger amount (~10\(^{-6}\) M) of vitamin A (retinol) is found in serum. The endogenous active retinoid is RA, which binds to and activates RAR\(\alpha\), \(\beta\), and \(\gamma\). Isomeric 13-cis-retinoic acid may also be an endogenous retinoid, but is less abundant than RA. 9-cis-Retinoic acid is synthesized from, or in equilibrium with, RA, and it binds to and activates RAR\(\alpha\), \(\beta\), and \(\gamma\), and in addition RXR \(\alpha\), \(\beta\), and \(\gamma\). Many synthetic analogs with a variety of structures have been prepared, and show different receptor selectivities and elicit different pharmacological effects from RA, including different adverse effects. Some act as antagonists which inhibit the activity of RA.

BIOLOGICAL AND PHARMACOLOGICAL ACTIVITIES OF RETINOIDS

The biological importance of RARs has been thoroughly documented elsewhere [14]. A number of genes are regulated directly through the RAR or RXR- response elements through retinoic acid or retinoids binding to RAR of the RAR/RXR heterodimers, or indirectly, plausibly through the participation of the directly-regulated genes [15]. The biological or pharmacological activities of interest here are
Towards Retinoid Therapy for Alzheimer’s Disease

Current Alzheimer Research, 2009, Vol. 6, No. 3

303

mostly covered in the above reviews [4-10]. An important practical clinical application of retinoids is in the treatment of acute promyelocytic leukemia (APL): treatment with RA results in complete remission in 90-95% of patients [16]. A synthetic retinoid, tamibarotene, works even on relapsed APL, which cannot be treated with RA [17]. Long-term maintenance treatments of APL patients using RA and tamibarotene are in progress. More recently a review of retinoids for cancer and metabolic disease was published [18]. Retinoids also inhibit angiogenesis [19]. Dermatological diseases, in particular psoriasis, are treated with RA, etretinate, and tamibarotene [20, 21]. Psoriasis is now regarded as an autoimmune disease [22]. Furthermore, retinoids are effective in the treatment of collagen-induced rheumatoid arthritis and other autoimmune models [23-25]. They are also useful to prevent atherosclerosis and restenosis of vascular vessels [26, 27]. Retinoids suppress the differentiation of preadipocytes to adipocytes [28], and promote alveolar regeneration in mammalian lungs [29]. Other observations suggest several clinical potential applications such as the treatment of diabetic retinopathy [30] and cataract [31]. Animal experiments using non-obese diabetic (NOD) mice suggested that retinoids may be effective to suppress type I diabetes and Schoegren’s syndrome [32]. Crohn’s disease is expected to be another treatment target [33, 34].

Retinoids appear to normalize many pathological states, and the clinical side effects presently reported are mostly not serious except for retinoic acid syndrome, which seems specific to APL pathogenesis. Teratogenicity remains an issue during the organ formation period in pregnancy; absolute contraception is required until complete clearance. Genotoxicity has not been observed. Skin irritation often becomes a limitation in prolonged use for some retinoids; this may be caused by activation of the RARγ [35-38].

ALZHEIMER’S PATHOPHYSIOLOGY

Current status of AD research are well summarized in a number of books, reviews, journals including this journal, and elsewhere such as web site reports [1-3, 39]. The major pathophysiology of AD is cerebral atrophy and neuronal loss, neuritic plaques and neurofibrillary tangles. Other important questions are being discussed such as “are inflammatory mechanisms actually causing damage in AD?” [40] or “immune cells may fend off Alzheimer disease” [41]. Cell therapies of degenerated neural cells and tissues are of cur-
rent interests, but relating to that, regeneration by retinoids
looks actual and now well-understood [42, 43]. Age-related
decline of cognition which is a serious feature of AD, could
also be a target phenomenon of a retinoid [44, 45]. Several
evidence for the relationships between the late onset Alz-
heimer’s disease and retinoid defective signaling are shown
[46, 47]. Now AD and other neurodegenerative diseases may
be likely the therapeutic targets of retinoid.

AMYLOID-β HYPOTHESIS

AD is characterized by progressive memory deficits, cognitive impairment and personality changes due to neu-
ronal cell death in the hippocampus and frontal cortex. The
histopathological hallmark of AD is senile plaques, which
consist of insoluble amyloid-β. Activated microglia and as-
trocytes (either proinflammatory or anti-inflammatory) sur-
round the amyloid plaques, and appear to be associated with
the lesions. Reduction of amyloid-β could be accomplished
by inhibiting its production or aggregation, or promoting its
degradation and removal, so active or passive immunization
may have therapeutic potential. It has been shown that amy-
loid-β specific antibodies can clear amyloid assemblies and
amyloid-β deposits in amyloid precursor protein (APP)-
transgenic mice. Amyloid-β-specific antibodies have been
extensively studied as a mediator of amyloid clearance [48].

APP is processed and fragmented by β-secretase and γ-
secretase to generate amyloid-β. However, the nonamyloi-
dogenic pathway of processing precursor proteins involves
cleavage within the amyloid-β peptide sequence. The identi-
fication of a member of the disintegrin and metalloprotease
family (ADAM10) as an α-secretase, whose expression can
be regulated by retinoic acid, represents another therapeutic
opportunity. Endogenous ADAM10 mRNA levels and the
ADAM10 promoter activities were increased on RA treat-
ment in neuroblastoma cells; thus, retinoic acid works as an
activator of the α-secretase [49-51].

Dietary deficiency of vitamin A disrupts the retinoid sig-
naling pathway in adult rats, leading to deposition of amy-
loid-β in the cerebral blood vessels via down-regulation of
RAR-α in the forebrain neurons and loss of choline acetyl-
transferase (ChAT) expression, and these changes were re-
versed by administration of retinoic acid [52, 53]. Pathologi-
cal samples from AD patients showed a similar RARα defi-
cit and deposition of amyloid-β in the surviving neurons
[52].

NEUROINFLAMMATION

For many years, the central nervous system was consid-
ered to be immunologically privileged, being neither suscep-
tible to, nor contributing to, inflammation. However, the
Neuroinflammation Working Group suggested a relationship
between inflammation and AD [40]. At least 600 reports
indicate that the brain is by no means an immunologically
isolated organ, and may have unique immunologic proper-
ties. Microglial-cell activation and migration, participation
of astrocytes, and participation of various cytokines in AD have
been confirmed. Microglia secrete proteolytic enzymes that
degrade amyloid-β, and play a neuroprotective role in AD.
One of the chemokine receptors, CCR2 deficiency impairs
microglial accumulation and accelerates the progression of
AD-like disease in a model mouse, Tg2576 [41, 54]. More
recently, Beers et al. showed CD4+ T cells, which can be
recruited by MCP-1/CCR2 signaling, provides supportive
neuroprotection by modulating the trophic/cytotoxic balance
of glia in ALS mouse mode [55].

Epidemiological studies indicate a reduced prevalence of AD
among chronic users of nonsteroidal anti-inflammatory
Drugs, and clinical trials suggested a beneficial effect of
some cyclooxygenase (cox) inhibitors, although the effect is
not related to the cox-inhibitory activity. Synthetic glucocor-
ticoids are potent anti-inflammatory agents that act by an-
tagonsing AP1 and NF-κB promoter elements that regulate
the transcription of inflammatory molecules. They are useful
for the treatment of inflammation, but various biochemical,
systemic and behavioral side effects and other contraindications
exist for use in AD. In their review [40], Akiyama et al.
concluded that “no more than nonsteroidal anti-inflammatory
drugs (NSAIDs) cure arthritis will anti-inflammatory drugs
cure AD. However, if AD neuroinflammation is approached
with realistic expectations and rational drug design, AD pa-
tients should significantly benefit from anti-inflammatory
treatment”. Suppression of inflammation in the brain is im-
portant in the treatment of many neurodegenerative diseases.

Other aspects of inflammation and immunology of neuro-
degenerative diseases have also recently been reviewed [56-
58]. Cytokines and chemokines, such as IL1α, IL1β, IL6,
IL4, IL10, IL13 and MCP-1 are also important in AD.
Though the action of IL6 generally depends on cellular and
environmental conditions, unlike that of IL1β, which pre-
dominantly has a proinflammatory effect, the cytokine may
generally exert a damaging proinflammatory effect in the
central nervous system, although it is present in normal brain
tissues [59]. IL6 dysregulation is involved in many age-
related diseases, including autoimmune diseases. Chronic
inflammation and astrocytosis are histopathological hall-
marks of AD patients, and astrocytes and microglia produce
IL6 in response to amyloid-β induced injury, thereby further
promoting plaque formation. The induction of IL6 mRNA in
the hippocampus and cortex of APPsw transgenic mice
Tg2576 may be crucial in the early onset of AD [60]. The
association of ~174G/C and ~572G/C mutations of IL6 pro-
moters with AD has been discussed, but remains contentious
[61, 62].

Since retinoids strongly suppress the production of IL6
[63, 64], the suppression of IL6 by retinoids may be benefi-
cial for the treatment of AD. Retinoids also inhibit LPS-
or amyloid-β-induced TNF-α production, and expression of
inducible NO synthase (iNOS) in activated microglia; these
effects may be mediated via the inhibition of NF-κB nuclear
translocation. Retinoids inhibit many aspects of microglial
activation [65, 66]. Thus, retinoids seem to have consider-
able potential from the standpoint of suppression of inflam-
mation in neurodegenerative diseases.

AUTOIMMUNE FEATURES

Immune system alterations during aging are complex and
pleiotropic. Generally, changes of the T cell component are
age-dependent. It is always difficult to determine whether
changes are associated with aging itself or a result (or a
cause) of disease. Although immunological studies of the
brain have been relatively limited because of the supposed immune privilege of the brain, the role of immunology cannot be neglected in AD (or PD), as well as in the representative autoimmune neurodegenerative disease, MS. It is, however, interesting that up-regulation of major histocompatibility complex (MHC) class I and II on glial and neural cells occurs in AD, in addition to production of inflammatory cytokines and limited T cell infiltration [40, 67], and the generation of autoreactive antibodies and T cells against amyloid-β [68]. Similar findings were reported in PD and ALS [69-72]. Thus, there is a possibility that an appropriate modulation of autoimmune response may prevent disease development. In other words, changes in the activity or population of T cells may influence the progression of AD, PD and other such diseases.

Recently, IL-17-producing helper T cell subset, Th17 is at the center of attention in autoimmune research [73, 74]. The importance of Th17 cells in central nervous system inflammation in MS patients and experimental autoimmune myasthenia gravis in C57BL/6 mice has been shown [75, 76]. IL17 and IL22 receptors are expressed on blood-brain-barrier (BBB) endothelial cells in MS lesions, and these cytokines disrupt BBB tight junctions in vivo and in vitro. Thus, Th17 lymphocytes transmigrate efficiently across the BBB, killing human neurons and causing central nervous system inflammation through CD4+ lymphocyte recruitment. It was also shown that the BBB induces differentiation of migrating monocytes into Th17-polarizing dendritic cells [77]. The abundance of dendritic cells promotes secretion of IL12p70, TGFβ and IL6, as well as the proliferation and expansion of distinct populations of IFNγ-secreting Th1, and IL-17-secreting CD4+ Th17 lymphocytes. Such cells are closely associated with microvascular BBB endothelial cells within acute MS lesions. It has also been shown that impairment of the function of tight junctions facilitates the invasion of inflammatory cells prior to motor neuronal degeneration in ALS-causing SOD1 mutant mice [78]. Similar BBB disruption may be involved in the early onset of AD, as well as other neurodegenerative disorders. The suppression of Th17 or the restoration or maintenance of the function of tight junctions has a favorable effect, slowing the progression of autoimmune diseases. It is noteworthy that experimental autoimmune encephalomyelitis (EAE) mice or rats, an animal model of MS, has been successfully treated with retinoid [79-81]. Psoriasis, which is an important clinical target of retinoid, is now regarded as an autoimmune disease [22].

T CELL DIFFERENTIATION

If T cells play a significant role in neurodegenerative diseases, their differentiation status must be important (Fig. 2). For two decades, it has been known that the CD4+ cells among the naïve T cells can differentiate into two types of helper T cells, Th1 cells, which express the transcription factor T-bet (activated by IFNγ), and Th2 cells, which express the transcription factor GATA3 (activated by IL4). In this classical Th1/Th2 paradigm, which is revised by recent emergence of Th17, Th1 activation appears particularly important in tissue-specific autoimmune such as EAE, and Th2 seems to be important in more systemic autoimmunity such as systemic lupas erythematosus (SLE) and allergic disease, though the key point is likely to be the balance between Th1 and Th2. It is noteworthy that the Th1 pathway is suppressed by RA (or retinoids), and the Th2 pathway is somewhat activated [82]. Retinoids are often beneficial for the treatment of autoimmune disease depending on the characteristics of the retinoid and the Th1/Th2 ratio of the disease [83]. A striking recent finding is that CD4+ naïve T cells, independently of Th1- and Th2-cell development, can differentiate to another helper T cell subset, Th17, which produces IL17 and expresses transcription factor retinoid-related orphan receptor γ (RORγt) [84]. Th17 cells are implicated in the pathogenesis of various autoimmune conditions, as mentioned in previous section, and supposed to be the major cause of rheumatoid arthritis, Crohn’s disease, psoriasis, MS and other diseases.

These effector T cells, Th1, Th2, and Th17 are suppressed by another CD4+ T cell subset of regulatory Tcells, Treg [85, 86]. A specific marker for Treg is the Foxp3 [87, 88]. The role of Treg cells in self-tolerance, autoimmune diseases and anti-tumor immunity has been actively studied in recent years. The decrease of Treg function may cause or progress breakdown of immune homeostasis. For example, the involvement of Treg has been demonstrated in MS [89], myasthenia gravis [90], and human T-lymphotropic virus 1 (HTLV-I) associated neuroimmunological disease [91]. Therapies for activation or proliferation of Treg may be useful for these autoimmune diseases.

This is also the case in the neurodegenerative diseases. Rosenkranz et al reported the involvement of Treg in AD and PD [92]. Analysis of Treg from AD and PD patients, as well as non-affected individuals, revealed that the frequency of Treg (CD4+ Foxp3+) increases with age and the increase is accompanied with intensified suppressive activity of Treg in patients. This may reflect a biological homeostatic response to the disease. Rosenkranz et al speculated that changes in Treg might affect disease-related immune mechanisms, since it has been hypothesized that neuroinflammation may be a response that is aimed at blocking disease development. The important role of Treg in PD was experimentally demonstrated in a MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-treated mouse model: Treg that highly expressed Foxp3 and IL10 was found to mediate neuroprotection through suppression of microglial activation [93].

In these respects, it is striking that CD4+ Foxp3+ T cell development from naïve CD4+ T cells is strongly induced by co-treatment with TGFβ and retinoid, including RA and synthetic retinoids such as Am580, and is suppressed by the retinoid antagonist LE540 [94-102] (Fig. 1). It is claimed that Treg is induced at the expense of IL17-secreting T cells by retinoic acid via RARα/RARβ (RORαt) [84]. Th17 cells are implicated in the pathogenesis of various autoimmune conditions, and hence the involvement of Th17 in AD is of special interest. The importance of Th17 cells in central nervous system inflammation is now recognized [73, 74]. The increase of Treg may be a response that is aimed at blocking disease development. The important role of Treg in AD was experimentally demonstrated in a MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-treated mouse model: Treg that highly expressed Foxp3 and IL10 was found to mediate neuroprotection through suppression of microglial activation [93].

In these respects, it is striking that CD4+ Foxp3+ T cell development from naïve CD4+ T cells is strongly induced by co-treatment with TGFβ and retinoid, including RA and synthetic retinoids such as Am580, and is suppressed by the retinoid antagonist LE540 [94-102] (Fig. 1). It is claimed that Treg is induced at the expense of IL17-secreting T cells by retinoic acid via RARαt [102]. However, it is not yet clear whether Th17 cells are convertible to Treg, and also whether or not Foxp3-positive cells induced by RA and retinoids are true Treg. Much remains unclear about the roles of the various T cell subsets, but the importance of retinoids in T cell differentiation seems now clear. And, there is a proposal as to whether oral tolerance is all due to RA [103], where the author expects the use of Treg cells in the clinic and new RAR agonists other than RA with less side effects for in vivo uses.
Infection could be a cause for breakdown of immune system and trigger autoimmune diseases. There is a hypothesis that AD is an autoimmune disease caused by an infection, but others have doubted a role of viral or other infection [104-106]. The role of infection with herpes simplex, spirochetes, and chlamyphilia in AD has recently been reviewed [67, 107-109]. A role of infection would be consistent with a recent report that a group of ALS patients showed an extremely high frequency of systemic mycoplasmal infections [110].

Various routes of infection, such as gut, nasal, skin and lung, involving viruses, bacteria, specific proteins and chemical substances have been discussed. The olfactory vector hypothesis is that xenobiotics, including viruses and toxins, immunologically pull the trigger leading to neurodegeneration [106, 111]. This hypothesis is supported by the finding that olfactory dysfunction is a risk factor for PD and AD [111-113]. The normal differentiation and regeneration of olfactory-related cells are also regulated by retinoic acid, and vitamin A therapy in animals with olfactory system damage can accelerate functional recovery through RARs and retinoid X receptors (RXRs): retinoic acid supports the integrity of the olfactory system throughout life [114, 115]. The maintenance of olfactory function by retinoid may be preventive for the disease. Pathogens may elicit an autoimmune response without persistence of the initiating agent, environmental factors and nutrition being critical determinants of the onset.

**REGENERATION OF NEURAL CELLS**

A possible approach to neurodegeneration is neural stem cell therapy. It is now well established that cells in the central nervous system can regenerate under certain conditions. Advances in techniques to isolate and manipulate neural stem cells offer new scope for functional recovery after central nervous system injuries.

Patterning into forebrain, midbrain, hindbrain, and spinal cord involves a complex series of morphogenetic movements. Further differentiation is also strictly regulated: for example, stem cells at the CA1 region of hippocampus differentiate into the neural cells of CA1. It is also important that regeneration stops at the appropriate point. In many cases of regeneration and differentiation in neural injuries, retinoic acid is involved, or retinal dehydrogenases (RALDH) are produced. For example, inflammation reactions caused by spinal cord contusion in rats were followed by an increase of RALDH2 enzyme activity and local synthesis of RA [116-118]. Intracellular translocation of RARα (and RXRs) into the nuclei of activated macrophages, surviving neurons and astrocytes near the lesion site has been reported [119]. The localization of retinoid receptors in Schwann cells correlated with inflammatory transduction pathways of IL-1β, IL-6 and TNFα [120].
The activities of RA in in-vitro differentiation, as well as in the development of vertebrates, have been known for a long time. RA can induce the complete regeneration of organs that cannot normally regenerate, such as mammalian lung and retina, by respecifying positional information [42, 121]. Murine P9 teratocarcinoma stem cells have been widely used as a model for cellular differentiation and RA signaling during embryonic development [122]. Induction of neural differentiation by retinoid has been shown in several embryonal carcinoma cell lines [123-125]. Many studies on pattern formation have confirmed the importance of retinoids in spinal cord and brain development [126]. These findings prompted detailed analyses of RARs in brain [127], and extensive studies of RAR signaling pathways in neurological diseases [47]. The results suggest that RA or more generally retinoids are potential therapeutic agents for the treatment of neurodegenerative diseases, promoting tissue regeneration. Studies are advanced in the case of acute phase treatment of SCI. Mey analyzed the distribution and re-distribution of RARs after SCI [119]. Maden showed the importance of RARs in SCI, and found that RARβ gene introduction and the coexistence of a RARβ ligand (rather than RARγ) caused neurite growth and improved the recovery of animals after trauma [126, 128, 129]. Takenaga recently observed similar therapeutic effect in physically injured rats treated with the synthetic retinoid tamibarotene [17] which is RARβ and RARβ specific (unpublished). Since the physical contusion is accompanied by inflammation and activation of microglia and macrophages, the therapeutic effect may not be simply explained, but at least re-generation and differentiation of neurite cells are promoted by retinoid in an adjuvant fashion.

Of course, other nuclear receptors (and their ligands) in addition to RARs participate, particularly RXRs, RORs, Liver X receptor (LXR), orphan nuclear receptor NR4A2 (Nurr1) [130], and peroxisome proliferators-activated receptors (PPARs) [131]. The expression profile and functional role of nuclear receptors in such retinoid signaling have been profiled in human SCI, ALS, AD and PD [132].

NEUROTRANSMISSION

Particular hallmarks observed in AD are the changes of cholinergic neurotransmission, which cause the decrease of acetylcholine (ACh). It was reported that vitamin A deficient rats with cognitive deficits showed impaired scopolamine-evoked release of ACh owing to blockade of the presynaptic acetylcholine autoreceptor. The impaired release of ACh is probably caused by lower production of ChAT, as well as neural cell death, mediated by RA and the gene promoter [133, 134].

An increase of ChAT seems to be beneficial, and it has been suggested that the vascular ACh transporter is also regulated by RA [135]. Retinoid rescued scopolamine-induced memory deficits in a passive avoidance paradigm [136]. This result could not be satisfactorily explained, but may support the participation of ACh and ChAT in the scopolamine-related memory deficit. In addition, retinoids also regulate the expression of tyrosine hydroxylase, dopamine β–hydroxylase and the dopamine D2 receptor. RA directly regulates D2 receptor expression via interaction with a RA-response element (RARE) at the promoter [137]. Such memory acquisition may not be explained simply by the participation of neurotransmitters.

LEARNING AND MEMORY

The physiological role of retinoids in hippocampal function of adult brain has been reviewed by Lane and Bailey [138]. The enzymes that synthesize RA and RALDH protein are restricted to the meninges surrounding the hippocampus in adult brain. The presence of cellular retinol binding protein 1 (CRABP1) and cellular retinoic acid binding protein 1 (CRABP1) in the dendritic layers of the hippocampal formation and dentate gyrus has been demonstrated. RARα and RARγ, rather than RAR-β, are highly expressed in hippocampal CA1, CA2 and CA3 regions. RXRs are also expressed. These findings suggest that RA (and therefore retinoids) may play a central role in memory and spatial learning. Impaired long-term potentiation (LTP) and long-term depression (LTD) have been demonstrated in mice lacking RAR β alone, or RAR β and RXR γ [139]. Loss of synaptic plasticity is observed in vitamin A deficient mice [44] or aged mice [140, 141]. The reductions of LTD and LTP are partially reversed by RA, although the precise involvement of specific genes in the regulation of synaptic plasticity has not been elucidated.

Etchamendy et al. [140] demonstrated that pharmacological activation of retinoid signaling by short-term RA administration to aged mice restored their hippocampal retinoid target-gene hypexpression, as well as their long-term declarative memory (LTDm) and hippocampal LTP deficit. Further, hippocampal retinoid receptor RARβ/RXRγ signaling is critically implicated in the cellular mechanism sustaining LTDm, as well as short-term working memory systems [45]. LTP-related genes, tyrosine kinase B (TrkB) and tissue plasminogen activator (t-PA), are reported to be the RAR-target genes and induced in neuroblastoma cells by treatment of retinoic acid [142-144]. TrkB is the receptor for brain-derived neurotrophic factor (BDNF), which is a key regulator for protein synthesis-dependent LTP and long-term memory and whose maturation is dependent on t-PA-mediated cleavage of proBDNF [145]. RARβ / RXRγ knock-out mice behaved similarly to the aged mice and it was shown that RARβ and expression of neuromodulin (Gap43) gene, a plasticity related retinoid-target gene, are important. This paper also reviewed the literature on this subject.

Another interesting observation was the involvement of transthyretin (TTR), which was identified as a key protein by microarray analysis of genes associated with age-related memory deficits [146]. TTR is a serum and cerebrospinal fluid carrier of the thyroid hormone, thyroxine. TTR is also a carrier of retinol from liver storage to target tissues in association with retinol binding protein (RBP) [147]. TTR has been reported to be the major amyloid-β binding protein in cerebrospinal fluid. Age-related memory deficits occurred in TTR/- mice in the water maze work task, and surprisingly, the deficits were improved by uptake of RA [146]. It has been shown that AD patients have lower levels of TTR [148]. TTR and possibly a similar serum protein, insulin-like growth factor I (IGF-I) regulate brain amyloid-β levels [149, 150]. Decreased levels of TTR may affect retinoid homeostasis, which is required to regulate neurogenesis and differentiation.
The appearance of new neurons in the hippocampus and cortex during adulthood seems to be linked to memory and learning [151]. Interestingly, in AD patients, an increased number of newly generated cells was observed in the granule cell layer, as well as the CA1 region of Ammon’s horn, where extensive cell death occurs during the disease [152]. Retinoids may have important roles in such neurogenesis.

CONCLUSION

Much research in AD is still aimed at elucidating basic pathomechanisms, although over seventy-five compounds are in clinical development for treatment of AD [39].

Retinoids are required for the maintenance of the immune systems, and are very potent immunomodulators. They suppressively regulate various autoimmune disease states, and being different from simple immunosuppressants, work physiologically even when applied at high pharmacological concentrations.

Retinoids are essential in the regeneration of neural cells and other tissues. Development of retinoids that are highly selective for individual RARs may contribute to the treatment of AD and other neurodegenerative diseases. Recently there came out a review emphasizing significant roles of retinoids for treatment of neurodegenerative diseases such as ALS, AD and schizophrenia [153]. We did not cover RXRs and RXR ligands here, though these may have a role in increasing the selectivity of retinoids, and they seem to have important roles in mental activities such as sleep regulation, reward-related behaviors [154-158].

Retinoids were suggested long ago to have potential for reward-related behaviors [154-158]. They are in clinical development for treatment of AD [39]. Much research in AD is still aimed at elucidating basic pathomechanisms, although over seventy-five compounds are in clinical development for treatment of AD [39].

Retinoids are required for the maintenance of the immune systems, and are very potent immunomodulators. They suppressively regulate various autoimmune disease states, and being different from simple immunosuppressants, work physiologically even when applied at high pharmacological concentrations.

Retinoids are essential in the regeneration of neural cells and other tissues. Development of retinoids that are highly selective for individual RARs may contribute to the treatment of AD and other neurodegenerative diseases. Recently there came out a review emphasizing significant roles of retinoids for treatment of neurodegenerative diseases such as ALS, AD and schizophrenia [153]. We did not cover RXRs and RXR ligands here, though these may have a role in increasing the selectivity of retinoids, and they seem to have important roles in mental activities such as sleep regulation, reward-related behaviors [154-158].

Retinoids were suggested long ago to have potential for the therapy of various proliferative diseases [159]. Some applications have been realized, and our task now is to extend the range of applications to neurodegenerative diseases, including AD.

ABBREVIATIONS

AD = Alzheimer’s disease
PD = Parkinson’s disease
ALS = Amyotrophic lateral sclerosis
MS = Multiple sclerosis
SCI = Spinal cord injury
RARs = Retinoic acid receptors
RA = all-trans-retinoic acid
APP = Amyloid precursor protein
ChAT = Choline acetyltransferase
Treg = Regulatory T cells
EAE = Experimental autoimmune encephalomyelitis
RXRs = Retinoid X receptors
RORs = Retinoid-related orphan receptors
RALDH = Retinal dehydrogenase
Ach = Acetylcholine
CRBP1 = Cellular retinol binding protein 1

CRBP1 = Cellular retinol binding protein 1
TTR = Transthyretin
APL = Acute promyelocytic leukemia

NOTE ADDED IN PROOFS

Ref. [160]

REFERENCES

[1] Cummings JL. Alzheimer’s disease. N Engl J Med 351: 56-67 (2004).
[2] Roberson ED, Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 314: 781-784 (2006).
[3] Hardy J. A hundred years of Alzheimer’s disease research. Neuron 52: 3-13 (2006).
[4] Sporn MB, Roberts AB, Goodman AB, Eds. The Retinoids. ACADEMIC PRESS, INC. 1(2): (1984).
[5] Dawson MI, Okamura WH, Eds. Chemistry and Biology of Synthetic Retinoids. CRC Press, Inc. (1990).
[6] Nau H, Blaner WS, Eds. Retinoids: The biochemical and molecular basis of vitamin A and retinoid action. Springer (1999).
[7] Kagechika H, Shudo K. Synthetic retinoids: recent developments concerning structure and clinical utility. J Med Chem 48: 5875-5883 (2005).
[8] Kagechika H. Novel synthetic retinoids and separation of the pleiotropic retinoidal activities. Curr Med Chem 9: 591-608 (2002).
[9] Dawson MI. Synthetic retinoids and their nuclear receptors. Curr Med Chem Anticancer Agents 4: 199-230 (2004).
[10] de Lera AR, Bourguet W, Altucci L, Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov 6: 811-820 (2007).
[11] Napoli JL. Retinoic acid: its biosynthesis and metabolism. Proc Nucleic Acid Res Mol Biol 63: 139-188 (1999).
[12] Ross AC. Retinoid production and catabolism: role of diet in regulating retinol esterification and retinoid Acid Oxidation. J Nutr 133: 291S-296S (2003).
[13] Blomhoff R, Blomhoff HK. Overview of retinoid metabolism and function. J Neurobiol 66: 606-630 (2006).
[14] Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, et al. International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol Rev 58: 712-725 (2006).
[15] Balmer JE, Blomhoff R. Gene expression regulation by retinoic acid. J Lipid Res 43: 1773-1808 (2002).
[16] Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111: 2505-2515 (2008).
[17] Miwako I, Kagechika H. Tamibarotene. Drugs Today (Barc) 43: 563-568 (2007).
[18] Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. Retinoic acid: its biosynthesis and metabolism. Proc Nucleic Acid Res Mol Biol 63: 139-188 (1999).
[19] Ross AC. Retinoid production and catabolism: role of diet in regulating retinol esterification and retinoid Acid Oxidation. J Nutr 133: 291S-296S (2003).
[20] Blomhoff R, Blomhoff HK. Overview of retinoid metabolism and function. J Neurobiol 66: 606-630 (2006).
[21] Balmer JE, Blomhoff R. Gene expression regulation by retinoic acid. J Lipid Res 43: 1773-1808 (2002).
[22] Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111: 2505-2515 (2008).
[23] Miwako I, Kagechika H. Tamibarotene. Drugs Today (Barc) 43: 563-568 (2007).
[24] Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov 6: 793-810 (2007).
[25] Oikawa T, Okayasu I, Ashino H, Morita I, Murota S, Shudo K. Three novel synthetic retinoids, Re 80, Am 580 and Am 80, all exhibit anti-angiogenic activity in vivo. Eur J Pharmacol 249: 113-116 (1993).
[26] Sardana K, Sehgal VN. Retinoids; fascinating up-and-coming scenario. J Dermatol 30: 355-380 (2003).
[27] Ishibashi Y. Clinical Effect of Am-80 Ointment on Psoiriasis and Pustulosis Palmaris et Plantaris (Phase III Study). Rinshou-Iyaku 11: 747-759 (1995).
[28] Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 11: 242-244 (2007).
[29] Kuwabara K, Shudo K, Hori Y. Novel synthetic retinoid acid inhibits rat collagen arthritis and differentially affects serum immunoglobulin subclass levels. FEBS Lett 378: 153-156 (1996).
[30] Nagai H, Matsuura S, Bouda K, Takaoka Y, Wang T, Niwa S, et al. Effect of Am-80, a synthetic derivative of retinoid, on experimental arthritis in mice. Pharmacology 58: 101-112 (1999).
[31] Beehler BC, Brinckerhoff CE, Ostrowski J. Selective retinoid acid receptor ligands for rheumatoid arthritis. Curr Opin Investig Drugs 5: 1153-1157 (2004).
[32] Wiegmans PJ, Barry WL, McPherson JA, McNamara CA, Gimple LW, Sanders JM, et al. All-trans-retinoic acid limits restenosis after
balloon angioplasty in the focally atherosclerotic rabbit: A favorable effect on vessel remodeling. Arterioscler Thromb Vasc Biol 20: 89-95 (2000).

[27] Fuji K, Manabe I, Ishihara A, Oishi Y, Iwata H, Nishimura G, et al. Synthetic retinoid Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima formation by inhibiting KLF5. Circ Res 97: 1132-1141 (2005).

[28] Sato M, Shudo K, Hiragun A. Functional studies of newly synthesized benzoic acid derivatives: identification of highly potent retinoid-like activity. J Cell Physiol 135: 179-188 (1988).

[29] Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med 3: 675-677 (1997).

[30] Nishikiori N, Osanai M, Chiba H, Kojima T, Ohguro H, et al. Glial cell-derived cytokines attenuate the breakdown of vascular integrity in diabetic retinopathy. Diabetes 56: 1333-1340 (2007).

[31] Nishikiori N, Osanai M, Chiba H, Kojima T, Ohguro H, Sawada N. Inhibitory effects of retinoic acid receptor alpha stimulants on murine cataractogenesis through suppression of deregulated calpains. Invest Ophthalmol Vis Sci 48: 2224-2229 (2007).

[32] Miwako I, Shudo K. Oral administration of synthetic retinoid Am80 inhibits the development of type 1 diabetes in NOD mice. Biol Pharm Bull (in press).

[33] Osanai M, Nishikiori N, Murata M, Chiba H, Kojima T, Sawada N. Cellular retinoic acid bioavailability determines epithelial integrity: Role of retinoic acid receptor alpha agonists in colitis. Mol Pharmacol 71: 250-258 (2007).

[34] Phase II Study of RR110 in Patients with Active Crohn's Disease [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00417391 [Accessed 2008 July 7]

[35] Standeven AM, Teng M, Chandraratna RA. Lack of involvement of retinoic acid receptor alpha in retinoïd-induced skin irritation in hairless mice. Toxicol Lett 92: 231-240 (1997).

[36] Iulianella A, Lohnes D. Contribution of retinoic acid receptor gamma to retinoid-induced craniofacial and axial defects. Dev Dyn 226: 237-244 (2003).

[37] Britschgi M, Wyss-Coray T. Immune cells may fend off Alzheimer disease. Nat Med 13: 408-416 (2007).

[38] Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-392 (2000).

[39] Mesner DL, Jacobs S, Shimizu Y, de Urquiza AM, Solomin L, Maden M. Retinoic acid, a regeneration-inducing molecule. Dev Dyn 226: 217-244 (2003).

[40] Maden M. Retinoic acid in the development, regeneration and function in late onset Alzheimer's disease. Nat Rev Neurosci 8: 575-765 (2007).

[41] Misner DL, Jacobs S, Shimizu Y, de Urquiza AM, Solomin L, Perlmann T, et al. Vitamin A deprivation results in reversible loss of hippocampal long-term synaptic plasticity. Proc Natl Acad Sci USA 98: 11714-11719 (2001).

[42] Mosca LD, Lipton SA, Greenberg SM, et al. Synthesis of a polyclonal antibody and its use for detection of apoE in human cerebrospinal fluid. J Neurochem 88: 870-878 (2001).

[43] Maeda K, Hata K, Takagi M, et al. ApoE4 increases cerebral amyloidosis in APPsw transgenic mice. Nat Med 12: 1088-1093 (2006).

[44] Mollon MJ, Stolin IG, Schindler K, et al. Retinoic acid receptor agonists suppress the production of IL-6 by activated rat microglia. Glia 54: 153-162 (2006).

[45] Mollon MJ, Stolin IG, Schindler K, et al. Retinoic acid receptor agonists suppress the production of IL-6 by activated rat microglia. Glia 54: 153-162 (2006).

[46] Prinzen C, Muller U, Endres K, Fahrenholz F, Postina R. Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J 19: 1522-1524 (2005).

[47] Fahrenholz F, Postina R. Alpha-secretase activation—an approach to Alzheimer’s disease therapy. Neurodegener Dis 3: 255-261 (2006).

[48] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[49] Prinzen C, Muller U, Endres K, Fahrenholz F, Postina R. Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J 19: 1522-1524 (2005).

[50] Fahrenholz F, Postina R. Alpha-secretase activation—an approach to Alzheimer’s disease therapy. Neurodegener Dis 3: 255-261 (2006).

[51] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[52] Prinzen C, Muller U, Endres K, Fahrenholz F, Postina R. Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J 19: 1522-1524 (2005).

[53] Fahrenholz F, Postina R. Alpha-secretase activation—an approach to Alzheimer’s disease therapy. Neurodegener Dis 3: 255-261 (2006).

[54] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[55] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[56] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[57] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[58] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[59] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[60] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[61] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[62] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[63] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[64] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[65] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[66] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[67] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[68] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[69] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).

[70] Fahrenholz F. Alpha-secretase as a therapeutic target. Curr Alzheimer Res 4: 412-417 (2007).
Wang T, Niwa S, Bouda K, Matsuura S, Homma T, Shudo K, Racke MK, Burnett D, Pak SH, Albert PS, Cannella B, Raine CS, Zhong Z, Deane R, Ali Z, Parisi M, Shapovalov Y, O'Banion MK, Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061 (2003).

McGeachy MJ, Cua DJ. Th17 cell differentiation: the long and winding road. Immunology 28: 445-453 (2008).

Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28: 454-467 (2008).

Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 13: 1173-1175 (2007).

Wang W, Milani M, Ostlie N, Okita D, Agarwal RK, Caspi RR, et al. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J Immunol 178: 7072-7080 (2007).

Ifergan I, Kebir H, Bernard M, Wosik K, Dodelet-Devillers A, Cayrol R, et al. The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 131: 785-799 (2008).

Zhong Z, Deane R, Ali Z, Parisi M, Shapovalov Y, O'Banion MK, et al. ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration. Nat Neurosci 11: 420-422 (2008).

Racke MK, Burnett D, Pak SH, Albert PS, Cannella B, Raine CS, et al. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol 155: 450-458 (1995).

Wang T, Niwa S, Bouda K, Matsuura S, Homma T, Shudo K, et al. The effect of Am-80, one of retinoid derivatives on experimental autoimmune encephalomyelitis in rats. Life Sci 67: 1869-1879 (2000).

Miyagawa N, Homma T, Kagechika H, Shudo K, Nagai H. Effect of synthetic retinoid, TAC-101, on experimental autoimmune disease. Pharmacololgy 67: 21-31 (2003).

Iwata M, Eshima Y, Kagechika H. Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Int Immunol 15: 1017-1025 (2003).

Fukasawa H, Kagechika H, Shudo K. Retinoid therapy for autoimmune diseases. Jpn J Clin Immunol 29: 114-126 (2006).

Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgamma directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126: 1121-1133 (2006).

Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing high levels of the CD25 molecule. Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Jpn J Clin Immunol 29: 114-126 (2006).

Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 9: 239-244 (2008).

Tang Q, Bluestone JA, Gerard HC, Gerard NM. A 10-item smell identification scale related to risk for Alzheimer's disease. Arch Gerontol Geriatr Suppl: 419-423 (2004).

Nicolson GL, Nasralla MY, Haier J, Pomfret J. High frequency of systemic mycoplasmal infections in Gulf War veterans and civilians with Amyotrophic Lateral Sclerosis (ALS). J Clin Neurosci 9: 525-529 (2002).

Deyneka A, LaMantia AS. A speculative essay on retinoic acid signaling in the developing and regenerating olfactory pathway. J Neurobiol 66: 653-676 (2006).

Rawson NE, LaMantia AS. A speculative essay on retinoic acid regulation of neural stem cells in the developing and aging olfactory system. Exp Gerontol 42: 46-53 (2007).

Mey J, Morassutti DJ, Brooks G, Liu RH, Zhang YP, Koopmans G, et al. Retinoic acid synthesis by a population of NG2-positive cells in the injured spinal cord. Eur J Neurosci 21: 1555-1568 (2005).

Mey J. New therapeutic target for CNS injury? The role of retinoic acid signaling after nerve lesions. J Neurobiol 66: 757-779 (2006).
Towards Retinoid Therapy for Alzheimer’s Disease

Current Alzheimer Research, 2009, Vol. 6, No. 3 311

[118] Kern J, Schrage K, Koopmans GC, Joosten EA, McCaffery P, Mey J. Characterization of retinaldehyde dehydrogenase-2 induction in NG2-positive glia after spinal cord contusion injury. Int J Dev Neurosci 25: 7-16 (2007).

[119] Zhelyaznik N, Mey J. Regulation of retinoic acid receptors alpha, beta and retinoid X receptor alpha after sciatic nerve injury. Neuroscience 141: 1761-1774 (2006).

[120] Mey J, Schrage K, Wessels I, Vollpracht-Crijns I. Effects of inflammatory cytokines IL-1beta, IL-6, and TNFalpha on the intracellular localization of retinoid receptors in Schwann cells. Glia 55: 152-164 (2007).

[121] Vergara MN, Arsenijevic Y, Del Rio-Tsonis K. CNS regeneration: a morphogen’s tale. J Neurobiol 64: 491-507 (2005).

[122] Strickland S, Mahdavi V. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell 15: 393-403 (1978).

[123] Kuff EL, Fewell JW. Induction of neural-like cells and acetylcholinesterase activity in cultures of F9 teratocarcinoma treated with retinoic acid and dibutyryl cyclic adenosine monophosphate. Dev Biol 77: 103-115 (1980).

[124] Liesi P, Rechardt L, Wartiovaara J. Nerve growth factor induces adrenergic neuronal differentiation in F9 teratocarcinoma cells. Nature 306: 265-267 (1983).

[125] McBurney MW, Jones-Villeneuve EM, Edwards MK, Anderson PJ. Control of muscle and neuronal differentiation in a cultured embryonal carcinoma cell line. Nature 299: 165-167 (1982).

[126] Maden M. Retinoids and spinal cord development. J Neurobiol 66: 726-738 (2006).

[127] Krezel W, Kastner P, Chambon P, Borrelli E. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell 15: 393-403 (1978).

[128] Wong LF, Yip PK, Battaglia A, Grist J, Corcoran J, Maden M, et al. Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord. Nat Neurosci 9: 243-250 (2006).

[129] Corcoran J, So PL, Barber RD, Vincent KJ, Mazarakis ND, Mitrophanous KA, et al. Retinoic acid receptor beta2 and neurite outgrowth in the adult mouse spinal cord in vitro. J Cell Sci 115: 3779-3786 (2002).

[130] Wallen-Mackenzie A, Mata de Urquiza A, Petersson S, Rodriguez FJ, Friling S, Wagner J, et al. Nurr1-RXR heterodimers mediate RXR ligand-induced signaling in neuronal cells. Genes Dev 17: 3036-3047 (2003).

[131] Heneka MT, Landreth GE. PPARs in the brain. Biochim Biophys Acta 1771: 1031-1045 (2007).

[132] Malaspina A, Turkheimer F. A review of the functional role and of the expression profile of retinoid signaling and of nuclear receptors in human spinal cord. Brain Res Bull 71: 437-446 (2007).

[133] Kobayashi M, Matsuoka I, Kurihara K. Cholinergic differentiation in human spinal cord. Brain Res Bull 71: 437-446 (2007).

[134] Pedersen WA, Berse B, Schulzer U, Wainer BH, Blusztajn JK. All-trans- and 9-cis-retinoic acid enhance the cholinergic properties of a murine septal cell line: evidence that the effects are mediated by activation of retinoic acid receptor-alpha. J Neurochem 65: 50-58 (1995).

[135] Berse B, Blusztajn JK. Coordinated up-regulation of choline acetyltransferase and vesicular acetylcholine transporter gene expression by the retinoic acid receptor alpha, cAMP, and leukemia inhibitory factor/ciliary neurotrophic factor signaling pathways in a murine septal cell line. J Biol Chem 270: 22101-22104 (1995).

[136] Shudo K, Kagechika H, Yamazaki N, Igarashi M, Tateda C. A morphogen’s tale. J Neurobiol 64: 491-507 (2005).

[137] Strickland S, Mahdavi V. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell 15: 393-403 (1978).

[138] Misner D, Kempermann G, Schikorski T, Giguere V, Sucov HM, et al. An essential role for retinoid receptors RARbeta and RXRgamma in long-term potentiation and depression. Neuron 21: 1353-1361 (1998).

[139] Chiang MY, Barres BA. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell 15: 393-403 (1978).

[140] Etchamendy N, Enderlin V, Marijetho J, Vouinam RM, Pallet V, Jaffard F, et al. Alleviation of a selective age-related relational memory deficit in mice by pharmacologically induced normalization of brain retinoid signaling. J Neurosci 21: 6423-6429 (2001).

[141] Krezel W, Enderlin V, Marijetho J, Vouinam RM, Higueret P, Jaffard F. Vitamin A deficiency and relational memory deficit in adult mice: relationships with changes in brain retinoid signalling. Behav Brain Res 145: 37-49 (2003).

[142] Lucarelli E, Kaplan DR, Thiele CJ. Selective regulation of TrkA and TrkB receptors by retinoid acid and interferon-gamma in human neuroblastoma cell lines. J Biol Chem 270: 24725-24731 (1995).

[143] Buleans F, Ibanez-Tallon I, Van Acker P, De Vriese M, Nelles L, Belayew A, et al. Retinoic acid induction of human tissue-type plasminogen activator gene expression via a direct repeat element (DRS) located at -7 kilobases. J Biol Chem 270: 7167-7175 (1995).

[144] Melchor JP, Strikland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 93: 655-660 (2005).

[145] Pang PT, Teng HK, Zatsnev E, Woo NT, Sakata K, Zhen S, et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 306: 487-491 (2004).

[146] Brouillette J, Quirion R, Tronchetti A. A key gene involved in the maintenance of memory capacities during aging. Neurobiol Aging 29: 1721-1732 (2008).

[147] Monaco HL. The transthyretin-retinol-binding protein complex. Biochim Biophys Acta 1482: 65-72 (2000).

[148] Merched A, Serot JM, Visvikis S, Aguillon D, Faure G, Siest G. Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer’s patients: relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett 425: 225-228 (1998).

[149] Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, et al. Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci USA 91: 8368-8372 (1994).

[150] Carro E, Trojo JL, Gomez-Isa T, LeRoith D, Torres-Aleman I. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8: 1390-1397 (2002).

[151] Kempermann G. Why new neurons? Possible functions for adult hippocampal neurogenesis. J Neurosci 22: 653-658 (2002).

[152] Jin K, Peel AL, Mao XO, Xie L, Cottrell BA, Henshall DC, et al. Increased hippocampal neurogenesis in Alzheimer’s disease. Proc Natl Acad Sci USA 101: 343-347 (2004).

[153] Malaspina A, Michael-Titus AT. Is the modulation of retinoid and retinoid-associated signaling a future therapeutic strategy in neurological trauma and neurodegeneration? J Neurochem 104: 584-595 (2008).

[154] Goodman AB. Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc Natl Acad Sci USA 95: 659-664 (1998).

[155] Maret S, Franken P, Dauvilliers Y, Ghyselinck NB, Chambon P, Bulens F, Ibanez-Tallon I, Van Acker P, De Vriese A, Nelles L, et al. Transcription factors Nur77 and retinoid X receptors participate in amphetamine-induced locomotor activities. Psycho-pharmacology (Berl) 202: 635-648 (2009).

[156] Levesque D, Rouillard C. Nur77 and retinoid X receptors: crucial factors in dopamine-related neuroadaptation. Trends Neurosci 30: 22-30 (2007).

[157] Leong MA, Bailey SJ. Role of retinoid signalling in the adult brain. Prog Neurobiol 75: 275-293 (2005).

[158] Sei H, Shibata T, Yamagishi M, Yamauchi Y, Ohyama T, Suwa Y, et al. Reduced expression of the retinoid X receptor in the hippocampus of Alzheimer’s disease patients. J Neurosci 28: 11622-11624 (2008).